ASCO China Perspective | Professor Benlong Yang: PREPEC Trial Shows Superior Quality of Life with Prepectoral Breast Reconstruction, but Higher Implant Loss Risk Requires Careful Consideration

ASCO China Perspective | Professor Benlong Yang: PREPEC Trial Shows Superior Quality of Life with Prepectoral Breast Reconstruction, but Higher Implant Loss Risk Requires Careful Consideration

As survival continues to improve for patients with breast cancer, postoperative quality of life (QoL) has become an increasingly important factor in surgical decision-making. Breast reconstruction is an integral component of comprehensive breast cancer care, and the choice of reconstructive technique has a profound impact on long-term functional recovery and psychosocial well-being.
ASCO China Perspective | Professor Jia Wang and Dr. Hao Yu: “Faster Is Not Always Better”—New Pooled Analysis Reframes Chemotherapy Strategies for High-Risk HR+/HER2− Early Breast Cancer

ASCO China Perspective | Professor Jia Wang and Dr. Hao Yu: “Faster Is Not Always Better”—New Pooled Analysis Reframes Chemotherapy Strategies for High-Risk HR+/HER2− Early Breast Cancer

Perioperative chemotherapy remains a cornerstone of treatment for patients with high-risk HR-positive/HER2-negative early breast cancer. Among the commonly used regimens, dose-dense anthracycline-taxane chemotherapy has long been considered a standard option. However, important clinical questions remain regarding the optimal timing of chemotherapy, patient selection, regimen composition, and treatment intensity.
BOC Spotlight on Precision HER2 Therapy | Disitamab Vedotin Sets a New Benchmark for China’s Homegrown Innovation

BOC Spotlight on Precision HER2 Therapy | Disitamab Vedotin Sets a New Benchmark for China’s Homegrown Innovation

In recent years, the treatment landscape for urothelial carcinoma (UC) has entered the era of precision medicine, with emerging therapeutic strategies offering new hope for patients. At the recent China Clinical Oncology Annual Advances Symposium (BOC) and Best of CSCO 2026 China, experts highlighted China's most significant original oncology achievements of the year and reviewed major advances in precision oncology across multiple tumor types, including genitourinary cancers, further advancing standardized cancer care in China.
ASCO China Voice | Professor Hui Xie: BMI May Serve as a Simple Stratification Marker for Trastuzumab Deruxtecan in Advanced Breast Cancer

ASCO China Voice | Professor Hui Xie: BMI May Serve as a Simple Stratification Marker for Trastuzumab Deruxtecan in Advanced Breast Cancer

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, a study led by Professor Hui Xie from Jiangsu Cancer Hospital was presented as an electronic poster (Abstract e13078). Using multicenter real-world data from China, the study is the first to systematically evaluate the relationship between body mass index (BMI) and the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive or HER2-low advanced breast cancer.
CSCO Leukemia Young Committee Perspectives | Bringing the Latest AML Advances from EHA 2026 Back to China 

CSCO Leukemia Young Committee Perspectives | Bringing the Latest AML Advances from EHA 2026 Back to China 

The 2026 European Hematology Association (EHA) Congress in Stockholm has concluded, unveiling a series of important advances in acute myeloid leukemia (AML). To help clinicians rapidly interpret the meeting's most impactful findings, the inaugural CSCO Leukemia Young Committee Perspectives webinar was held on June 14 through a collaboration between the CSCO Leukemia Youth Committee and Hematology Frontier. The program was chaired by Professor Qiu Shaowei, Chair of the CSCO Leukemia Committee Youth Group from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS). Joining the discussion were Professor Pei Shanzhan from the First Affiliated Hospital, Zhejiang University School of Medicine and Liangzhu Laboratory, Professor Tang Feifei from Peking University People's Hospital, and Professor Cao Yigeng from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS). Together, they provided an in-depth review of the latest AML research presented at EHA 2026, highlighting its clinical significance and future implications.
Precise Characterization of Transplant Prognosis: From DTA Mutation Monitoring to TP53 Aberration Stratification, Experts at EHA 2026 Discuss Changing Landscape of Myeloid Neoplasm Treatment 

Precise Characterization of Transplant Prognosis: From DTA Mutation Monitoring to TP53 Aberration Stratification, Experts at EHA 2026 Discuss Changing Landscape of Myeloid Neoplasm Treatment 

The 2026 European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain. As one of the most influential academic events in the global hematology field, the application of allo-HSCT in myeloid neoplasms remains a focus of academic debate and innovation. This specialized session, chaired by Professor Anna Sureda (Catalan Institute of Oncology, Barcelona, Spain), focused on post-transplant molecular monitoring, refinement of prognostic strategies, and algorithm optimization for refractory cases in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Research teams from China, Switzerland, Sweden, Spain, and other countries shared five milestone academic reports, providing new evidence-based medical grounds for clinical precision transplantation.
ASCO China Voice | Prof. Junxing Chen: PUNCH03 Demonstrates Early Promise as Disitamab Vedotin Plus BCG Offers a New Chinese Strategy for High-Risk NMIBC 

ASCO China Voice | Prof. Junxing Chen: PUNCH03 Demonstrates Early Promise as Disitamab Vedotin Plus BCG Offers a New Chinese Strategy for High-Risk NMIBC 

Transurethral resection of bladder tumor (TURBT) remains the standard treatment for non-muscle-invasive bladder cancer (NMIBC). However, up to 45% of patients experience tumor recurrence within one year following TURBT alone. Although intravesical therapies—including cytotoxic agents and immunotherapy—are widely used, substantial unmet clinical needs remain, underscoring the need for more effective treatment strategies.
Breaking the MM Treatment Burden: Precision Prevention of Infection, Optimization of Administration Routes, and Future Outlook for Trispecific Antibodies 

Breaking the MM Treatment Burden: Precision Prevention of Infection, Optimization of Administration Routes, and Future Outlook for Trispecific Antibodies 

At the 2026 European Hematology Association (EHA) Annual Meeting, managing the treatment burden of multiple myeloma (MM) became a core topic. As innovative therapies such as bispecific antibodies (BsAbs) and CAR-T enter clinical practice, how to reduce patient infection risks, optimize the convenience of administration, and improve quality of life while pursuing deep remission has become a major challenge for clinicians. This meeting invited Professor Joseph Mikhael from City of Hope, Professor Maria-Victoria Mateos from the University Hospital of Salamanca, and Professor Xavier Leleu from Poitiers University Hospital to conduct an in-depth discussion on "Managing the Burden of MM Treatments."